J&J Medical Connect
TREMFYA®

(guselkumab)

+ Save link

Medical inquiries

Connect with my medical science liaison

Connect with my medical science liaison

Chat live

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Email your inquiry

Call 1-800-526-7736

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TREMFYA® (guselkumab)

Medical Information

TREMFYA – Switching from TREMFYA to Other Biologics in Crohn's Disease or Ulcerative Colitis

Last Updated: 06/23/2025

SUMMARY

  • The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
  • The phase 3 clinical trial program of TREMFYA in the treatment of adults with moderately to severely active Crohn's disease or ulcerative colitis did not evaluate the switching of TREMFYA to other biologics.1-3

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 23 June 2025.

 

References

Show
1 Janssen Research & Development, LLC. A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease (GALAXI). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2025 June 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03466411 NLM Identifier: NCT03466411.  
2 Janssen Research & Development, LLC. A study of guselkumab in participants with moderately to severely active ulcerative colitis (QUASAR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 - [cited 2025 June 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT04033445 NLM Identifier: NCT04033445.  
3 Janssen Research & Development, LLC. A study of guselkumab subcutaneous therapy in participants with moderately to severely active Crohn’s disease (GRAVITI). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2025 June 23]. Available from: https://clinicaltrials.gov/study/NCT05197049 NLM Identifier: NCT05197049.  
Endchat
Chat live